Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

181. Glecaprevir and pibrentasvir (Mavyret) - To treat adults with chronic hepatitis C virus

Glecaprevir and pibrentasvir (Mavyret) - To treat adults with chronic hepatitis C virus Drug Approval Package: MAVYRET (glecaprevir and pibrentasvir) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: MAVYRET (glecaprevir and pibrentasvir) Company: AbbVie Inc. Application No.: 209394Orig1s000 Approval Date: August 3, 2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF

FDA - Drug Approval Package2017

182. Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) - To treat adults with chronic hepatitis C virus

Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) - To treat adults with chronic hepatitis C virus Drug Approval Package: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) Company: Gilead Sciences, Inc. Application No.: 209195Orig1s000 Approval Date: July 18, 2017 Persons with disabilities having problems accessing the PDF files below may call (301

FDA - Drug Approval Package2017

183. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review

Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review 29226101 2018 11 13 2225-0719 5 4 2017 Dec 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. 343-362 10.14218/JCTH.2017.00021 Hepatitis C (HCV) infection has an estimated global prevalence of 2.5%, causing chronic liver disease in 170 million people worldwide. Recent data has identified HCV infection as a risk factor (...) , USA. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. eng K23 HL133358 HL NHLBI NIH HHS United States Journal Article Review 2017 08 31 China J Clin Transl Hepatol 101649815 2225-0719 Atherosclerosis Cardiovascular disease Cerebrovascular disease Coronary heart disease Hepatitis C The authors have no conflict of interests related to this publication. 2017 03 13 2017 07 15 2017 07 27 2017 12 12 6 0 2017 12 12 6 0 2017 12 12 6 1 ppublish 29226101 10.14218

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

184. Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends

Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends 29291208 2018 11 13 2347-3584 28 3 2017 Sep Virusdisease Virusdisease Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends. 233-241 10.1007/s13337-017-0393-5 Prevalence of hepatitis C infection, which is associated with mortality and morbidity, is higher in chronic kidney disease patients on hemodialysis and transplant recipients when compared to non HCV (...) infected patients. In addition to the conventional risk factors, HCV infection maybe an additional risk factor in the development of chronic kidney disease. HCV causes adverse effects leading to the poor long term outcome in renal transplant recipients; hepatitis C infection can cause both hepatic as well as extra hepatic complications. Prior evaluation and management of HCV infection is recommended for better long term outcome as there are chances of higher rejection rates with HCV treatment. However

Virusdisease2017 Full Text: Link to full Text with Trip Pro

185. Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection

Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection 29291215 2018 11 13 2347-3584 28 3 2017 Sep Virusdisease Virusdisease Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection. 289-294 10.1007/s13337-017-0391-7 TP53 and phosphate and tension homolog (PTEN) are two tumor suppressor genes that regulate cell proliferation, migration, and death. P53 and PTEN deficiency has (...) been associated with hepatic fibrosis, a prominent pathological feature associated with chronic hepatitis B (CHB). The present study is aimed to assess the association of PTEN 32-bp Ins/Del (rs34421660) and TP53 16-bp Ins/Del polymorphisms with CHB infection susceptibility. A total of 411 subjects were recruited in this case-control study of 213 patients with CHB infection and 198 healthy individuals as controls. PTEN and TP53 deletions were detected by polymerase chain reaction method. We found

Virusdisease2017 Full Text: Link to full Text with Trip Pro

186. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection 29404492 2018 11 13 2471-254X 1 8 2017 10 Hepatology communications Hepatol Commun Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. 757-764 10.1002/hep4.1081 Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations (...) of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, leading to challenging treatment failures due to the development of resistance-associated substitutions. This post-hoc analysis assessed 12-week sustained viral response (SVR12) and pharmacokinetics of fixed-dose combination elbasvir/grazoprevir (EBR/GZR) in patients with HCV infection and self-reported PPI use. Data were derived

Hepatology communications2017 Full Text: Link to full Text with Trip Pro

187. Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors

Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors 29226099 2018 11 13 2225-0719 5 4 2017 Dec 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors. 327-334 10.14218/JCTH.2017.00017 Background and Aims : Direct-acting antiviral (DAA) therapy is the cornerstone of the treatment of chronic (...) hepatitis C virus (HCV) infection. Eradication of HCV, predicted by the attainment of a sustained virologic response (SVR) 12 weeks following DAA therapy, is the goal of this treatment. Interestingly, recent studies have reported the possible association between HCV-infected patients with DAA therapy concomitant use of proton pump inhibitors (PPIs) and lower odds of achieving SVR. This meta-analysis was conducted to summarize all available data and to estimate this potential association. Methods

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

188. Hepatitis E: A Literature Review

Hepatitis E: A Literature Review 29226104 2018 11 13 2225-0719 5 4 2017 Dec 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Hepatitis E: A Literature Review. 376-383 10.14218/JCTH.2017.00012 Hepatitis E is the fifth known form of human viral hepatitis. Although not very common in our clinical practice, the incidence in Western countries is increasing. Infection with the hepatitis E virus (HEV) may be related to acute illness, liver failure, chronic hepatitis (...) and cirrhosis. HEV itself is an RNA virus, with eight described genotypes (HEV 1-8), four of which more commonly affect humans and have, thus, been better studied. Besides liver manifestations, genotype 3 is also related to extra-hepatic manifestations, such as neurological, renal and rheumatological. Evolution to chronic disease occurs especially in patients who underwent transplantation, have hematological malignancies requiring chemotherapy, or have infection with the human immunodeficiency virus

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

189. Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000‐2014)

Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000‐2014) 29404490 2018 11 13 2471-254X 1 8 2017 10 Hepatology communications Hepatol Commun Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). 736-747 10.1002/hep4.1073 We assessed trends in HCC survival in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV (...) improved from 0.6 years (95% confidence interval [CI] 0.39-1.28) in 2000-2004 to 2.8 years (1.54-5.54) in 2010-2014. Median survival following first HCV-HCC hospitalization was 0.8 years (0.45-1.33) in 2000-2004 and 0.9 (0.67-1.18) in 2010-2014. One-year HBV-HCC survival in 2010-2014 compared to 2000-2004 improved for those with (94% versus 81%) and without (42% versus 33%) potentially curative procedures (liver resection, liver transplantation, and radiofrequency ablation). Factors associated

Hepatology communications2017 Full Text: Link to full Text with Trip Pro

190. Role of gp91phox in hepatic macrophage programming and alcoholic liver disease

Role of gp91phox in hepatic macrophage programming and alcoholic liver disease 29404493 2018 11 13 2471-254X 1 8 2017 10 Hepatology communications Hepatol Commun Role of gp91 phox in hepatic macrophage programming and alcoholic liver disease. 765-779 10.1002/hep4.1078 Hepatic macrophages (M Φ s) are important in the development and progression of alcoholic liver disease (ALD). This study investigates the role of gp91 phox (nicotinamide adenine dinucleotide phosphate oxidase 2) in the severity (...) of ALD and specifically in regulating hepatic M Φ efferocytic capability and the subsequent reprogramming associated with resolution of inflammation. After 4 weeks of ethanol feeding, more severe ALD developed in gp91 phox-/- mice than in wild-type (WT) C57Bl/6J mice, evidenced by increased liver injury and inflammation. This phenomenon was not sex dependent, and thus the majority of experiments were performed with female mice. While total hepatic M Φ numbers did not differ between genotypes, hepatic

Hepatology communications2017 Full Text: Link to full Text with Trip Pro

191. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Background: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of disease cure; however, not enough specialists currently are available to provide care. Objective: To determine the efficacy of HCV treatment independently provided by nurse practitioners (NPs), primary care physicians (PCPs

Annals of Internal Medicine2017 Full Text: Link to full Text with Trip Pro

192. Evaluation of Hepatic Fibrosis: A Review from the Society of Abdominal Radiology Disease Focus Panel

Evaluation of Hepatic Fibrosis: A Review from the Society of Abdominal Radiology Disease Focus Panel 28624924 2017 11 21 2018 11 13 2366-0058 42 8 2017 08 Abdominal radiology (New York) Abdom Radiol (NY) Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. 2037-2053 10.1007/s00261-017-1211-7 Hepatic fibrosis is potentially reversible; however early diagnosis is necessary for treatment in order to halt progression to cirrhosis and development (...) of complications including portal hypertension and hepatocellular carcinoma. Morphologic signs of cirrhosis on ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) alone are unreliable and are seen with more advanced disease. Newer imaging techniques to diagnose liver fibrosis are reliable and accurate, and include magnetic resonance elastography and US elastography (one-dimensional transient elastography and point shear wave elastography or acoustic radiation force impulse imaging

Abdominal radiology (New York)2017 Full Text: Link to full Text with Trip Pro

193. The Impact of Silymarin on Improvement of Hepatic Abnormalities in Patients with Severe Preeclampsia: A Randomized Clinical Trial

The Impact of Silymarin on Improvement of Hepatic Abnormalities in Patients with Severe Preeclampsia: A Randomized Clinical Trial 28979748 2018 11 13 2008-5842 9 8 2017 Aug Electronic physician Electron Physician The Impact of Silymarin on Improvement of Hepatic Abnormalities in Patients with Severe Preeclampsia: A Randomized Clinical Trial. 5098-5106 10.19082/5098 Preeclampsia is a pregnancy-specific disorder, associated with increased blood pressure and proteinuria, and in extreme cases (...) it can also cause liver and kidney problems. To determine the impact of silymarin on the improvement of severe preeclampsia. This randomized clinical trial was conducted at Hajar Hospital in Shahrekord, Iran, from April 2014 to September 2015. Sixty patients whose pregnancy had ended as a result of severe preeclampsia, were entered into the study. Patients were randomly divided into two groups of thirty study and control groups. In addition to current treatment for preeclampsia, case groups were

Electronic physician2017 Full Text: Link to full Text with Trip Pro

194. Maviret (glecaprevir / pibrentasvir) - chronic (long-term) hepatitis C

Maviret (glecaprevir / pibrentasvir) - chronic (long-term) hepatitis C 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 22 June 2017 EMA/449689/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Maviret (...) of abbreviations AASLD American Association for the Study of Liver Disease AE adverse event ALT alanine aminotransferase AUC area under the plasma concentration-time curve AUC 24 area under the plasma concentration-time curve for the 24-hour dosing interval BCRP breast cancer resistance protein BMI body mass index BOC boceprevir BP baseline polymorphism BSEP bile salt export pump CHMP Committee for Medicinal Products for Human Use CI confidence interval CKD chronic kidney disease Cmax maximum plasma

European Medicines Agency - EPARs2017

195. Ibrutinib (Imbruvica): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections

Ibrutinib (Imbruvica): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections - GOV.UK GOV.UK uses cookies to make the site simpler. Search Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections From: Published: 15 August 2017 Therapeutic area (...) : , , , , and Temporarily discontinue ibrutinib in patients who develop symptoms suggestive of ventricular arrhythmia and assess benefit-risk before restarting therapy. Establish hepatitis B virus status before initiating ibrutinib. Consider prophylaxis for patients who are at an increased risk of opportunistic infections. Contents Advice for healthcare professionals: cases of ventricular tachyarrhythmia have been reported temporarily discontinue ibrutinib in patients who develop symptoms suggestive of ventricular

MHRA Drug Safety Update2017

196. Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation

Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation - GOV.UK GOV.UK uses cookies to make the site simpler. Search Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor (...) for opportunistic infections, hepatitis B reactivation From: Published: 20 July 2017 Therapeutic area: , , and Recent clinical trials have shown increased mortality when bendamustine (Levact) was used in combination treatments outside its approved indications. Be aware that the risk of opportunistic infections for all patients receiving bendamustine including those receiving off-label treatment may be greater than previously recognised. Be aware of your responsibilities if prescribing bendamustine outside

MHRA Drug Safety Update2017

197. Elbasvir/Grazoprevir (chronische Hepatitis C) - Nutzenbewertung gemäß § 35a SGB V

Elbasvir/Grazoprevir (chronische Hepatitis C) - Nutzenbewertung gemäß § 35a SGB V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Elbasvir/Grazoprevir (chronische Hepatitis C) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 10 March 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A16-75 (...) Elbasvir/grazoprevir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A16-75 Version 1.0 Elbasvir/grazoprevir (chronic hepatitis C) 10 March 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Elbasvir/grazoprevir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint

Institute for Quality and Efficiency in Healthcare (IQWiG)2017

198. Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V

Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V Extract 1 Translation of Sections 2.1 to 2.13 of the dossier assessment Sofosbuvir/Velpatasvir (chronische Hepatitis C) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 October 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission (...) No. A16-48 Sofosbuvir/velpatasvir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A16-48 Version 1.0 Sofosbuvir/velpatasvir (chronic hepatitis C) 13 October 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V Commissioning agency

Institute for Quality and Efficiency in Healthcare (IQWiG)2017

199. Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48

Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48 1 Translation of addendum A16-73 Sofosbuvir/Velpatasvir (chronische Hepatitis C) – Addendum zum Auftrag A16-48 (Version 1.0; Status: 8 December 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 8 December 2016 1.0 Commission: A16-73 Version: Status: IQWiG Reports (...) – Commission No. A16-73 Sofosbuvir/velpatasvir (chronic hepatitis C) – Addendum to Commission A16-48 1 Addendum A16-73 Version 1.0 Sofosbuvir/velpatasvir – Addendum to Commission A16-48 8 December 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir (chronic hepatitis C) – Addendum to Commission A16-48 Commissioning agency: Federal Joint Committee Commission awarded on: 23

Institute for Quality and Efficiency in Healthcare (IQWiG)2017

200. Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease

Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease 29404483 2018 11 13 2471-254X 1 7 2017 09 Hepatology communications Hepatol Commun Characteristics of hepatic insulin-sensitive nonalcoholic fatty liver disease. 634-647 10.1002/hep4.1077 Nonalcoholic fatty liver disease (NAFLD) plays a crucial role in type 2 diabetes and hepatocellular carcinoma. The major underlying pathogenesis is hepatic insulin resistance. The aim of the present study was to characterize (...) patients with NAFLD with paradoxically normal hepatic insulin sensitivity relative to patients with NAFLD with hepatic insulin resistance. We recruited 26 patients with NAFLD and divided them into three groups ranked by the level of hepatic insulin sensitivity (HIS; high-HIS, mid-HIS, low-HIS), as assessed by the hyperinsulinemic-euglycemic clamp studies using stable isotope. Hepatic insulin sensitivity of the high-HIS group was identical to that of the non-NAFLD lean control (clamped percent

Hepatology communications2017 Full Text: Link to full Text with Trip Pro